GlaxoSmithKline and Prosensa today conceded defeat in the Phase III study for drisapersen, one of two closely-watched therapies for Duchenne muscular dystrophy which had been vying for the lead in the field. Investigators reported that the therapy failed to significantly improve walking distance in patients.
The money will be used, in part, to pay for a mid-stage study of MOR208, its anti-CD19 antibody for chronic lymphocytic leukemia as well as new studies of MOR202, an anti-CD38 antibody currently in a Phase I/IIa clinical trial in multiple myeloma.
When ChemoCentryx reported last month that its Crohn's disease drug vercirnon (GSK1605786) failed the first of four Phase III trials mounted by GlaxoSmithKline, the biotech said it was awaiting word from the pharma giant on its future development plans.
Shares of NovaBay Pharmaceuticals shot up 11% after the Emeryville, CA-based biotech said that a mid-stage study of a new solution to prevent problems for people with indwelling urinary catheters proved successful, paving the way for a late-stage trial.
Israel's Pluristem Therapeutics says the FDA has given the company a green light to push ahead on a mid-stage study of one of its stem cell therapies after the agency had finished its review of one patient's severe allergic reaction and tweaked the trial protocol.
Investigators tested the antiviral among hematopoietic cell transplant recipients with early adenovirus infection, but said--well into its release--that the therapy fell short on achieving statistical significance on efficacy in the "progression to possible or probable AdV disease or significant changes in AdV viremia.
Neurocrine shares took a nasty drubbing after the biotech announced that its low-dose version of an experimental therapy for a rare movement disorder failed a Phase IIb study.
Shares of Canada's Oncolytics surged again this morning after the biotech reported out a final analysis on its tumor virus Reolysin, showing a 92% response rate among a small group of 25 patients enrolled in a Phase II study.
After big gains in its stock price, Biodel shares slipped more than 20% this morning on the back of mid-stage trial results for its fast-acting, mealtime insulin candidate.
CRO giant Covance has signed a deal with the Indiana University School of Medicine, bringing more Phase I studies to the school's on-site clinical research unit and giving Covance a broader footprint for early trials.